Top Markets
Coin of the day
Medigene AG Medigene AG

Medigene AG

MDG1
Rank in Stocks #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Universitรฉ de Montrรฉal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Share Price
$0.14942078
Last synced: 2025-05-15
Market Cap
$3.86M
Change (1 day)
0.10%
Change (1 year)
0.00%
Country
DE
Trade Medigene AG (MDG1)

Category

Stock split history for Medigene AG (MDG1)
Medigene AG stock (symbol: MDG1) underwent a total of 2 stock splits.
The most recent stock split occurred on Aug 29, 2024.
One MDG1 share bought prior to Sep 03, 2013 would equal to 0.125 MDG1 shares today.
Stock split list
Year Split Multiple Cumulative Multiple
2024-08-29 1:2 x0.5 x0.125
2013-09-03 1:4 x0.25 x0.25
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE